H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BerGenBio AS (BRRGF – Research Report) today and set a price target of NOK66.00. The company’s shares closed last Monday at $1.23, equals to its 52-week low of $1.23.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 15.8% and a 48.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BerGenBio AS with a $6.33 average price target.
The company has a one-year high of $2.51 and a one-year low of $1.23. Currently, BerGenBio AS has an average volume of 217.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.